Utama › Kanser Paru-paru › Oregon › Portland
Kajian klinikal Kanser Paru-paru di Portland, OR
26 kajian untuk Kanser Paru-paru sedang mencari peserta di lokasi dalam dan sekitar Portland (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.
Teks kajian rasmi (Bahasa Inggeris)
Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Mengambil pesertaFasa 3
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- Kaiser Permanente Northwest, Portland
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Mengambil pesertaFasa 1/2
- Oregon Health & Science University (OHSU), Portland
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- Providence Willamette Falls Medical Center, Oregon City · 12 mi jauh
A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)
Mengambil pesertaFasa 1/2
- Providence Portland Medical Center ( Site 0043), Portland
- Providence Oncology and Hematology Care Clinic - Westside ( Site 0059), Portland
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
Mengambil pesertaFasa 3
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Mengambil pesertaFasa 3
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- Oregon Health and Science University, Portland
A Study of PHN-012 in Patients With Advanced Solid Tumors
Mengambil pesertaFasa 1
- PHN-012-001 Site, Portland
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
Mengambil pesertaFasa 3
- Oregon Health and Science University ( Site 0052), Portland
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Mengambil pesertaFasa 3
- Northwest Cancer Specialists, P.C., Portland
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
Mengambil pesertaFasa 1/2
- Providence Portland Medical Center, Portland
- Providence St. Vincent Medical Center, Portland
- Local Institution - 0052, Portland
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
Mengambil pesertaFasa 2/3
- Providence Portland Medical Center, Portland
- Kaiser Permanente Interstate Medical Office Central, Portland
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
Mengambil pesertaFasa 2/3
- Providence Cancer Institute Franz Clinic, Portland
- Providence St. Vincent Medical Center, Portland
- Oregon Health and Science University, Portland
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Mengambil pesertaFasa 1
- Providence Portland Medical Center, Portland
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Mengambil pesertaFasa 3
- Oregon Health and Science University, Portland
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Mengambil pesertaFasa 3
- Providence Portland Medical Center, Portland
- Providence St. Vincent Medical Center, Portland
- Kaiser Permanente Interstate Medical Office Central, Portland
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
Mengambil pesertaFasa 3
- Legacy Good Samaritan Hospital and Medical Center, Portland
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
Mengambil pesertaFasa 1/2
- Providence Portland Medical Center, Portland
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
Mengambil pesertaFasa 2
- Oregon Health and Science University, Portland
Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study
Mengambil pesertaFasa 4
- OHSU Knight Cancer Institute, Portland
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Mengambil pesertaFasa 2
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- Kaiser Permanente Northwest, Portland
- dan 2 lagi
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Mengambil pesertaFasa 2
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- Kaiser Permanente Northwest, Portland
- dan 2 lagi
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Mengambil pesertaFasa 2/3
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- Oregon Health and Science University, Portland
- dan 1 lagi
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
- Oregon Health Sciences University, Portland
LOTUS-CC: An Observational Research Study to Uncover Subtypes of Cancer Cachexia
Mengambil pesertaKajian pemerhatian
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- Providence Willamette Falls Medical Center, Oregon City · 12 mi jauh
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Mengambil pesertaKajian pemerhatian
- Massive Bio SYNERGY-AI site, Portland
Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening
Mengambil pesertaKajian pemerhatian
- Oregon Health & Science University, Portland
Kajian Kanser Paru-paru di bandar lain
- Houston, TX78 kajian
- Boston, MA62 kajian
- New York City, NY60 kajian
- Los Angeles, CA45 kajian
- Washington, DC41 kajian
- Arlington, VA41 kajian
- Chicago, IL41 kajian
- Nashville, TN40 kajian
- Baltimore, MD40 kajian
- St. Louis, MO39 kajian
- Columbus, OH37 kajian
- Philadelphia, PA36 kajian
Kajian lain di Portland
- Kanser Paru-paru Bukan Sel Kecil46 kajian
- Kanser (semua jenis)34 kajian
- Kanser Prostat33 kajian
- Kanser Payudara33 kajian
- Kanser Metastatik29 kajian
- Kanser Kolorektal28 kajian
- Kanser Ovari27 kajian
- Leukemia Mieloid Akut25 kajian
- Kanser Endometrium24 kajian
- Karsinoma Sel Skuamosa Kepala dan Leher19 kajian
- Kanser Pankreas19 kajian
- Kegagalan Jantung17 kajian
Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.